gms | German Medical Science

22nd Annual Meeting of the German Retina Society

German Retina Society

26.06. - 27.06.2009, Berlin

Transarterial chemoembolization (TACE) of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome

Meeting Abstract

  • Alexander Schmittel - Charité-Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Benjamin Franklin
  • R. Schuster - Charité-Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Benjamin Franklin
  • M. Lindner - Charité-Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Benjamin Franklin
  • F. Wacker - Charité-Universitätsmedizin Berlin, Radiologie, Campus Benjamin Franklin
  • M. Krössin - Charité-Universitätsmedizin Berlin, Radiologie, Campus Benjamin Franklin
  • N. E. Bechrakis - Universitäts-Augenklinik Innsbruck
  • M. H. Foerster - Charité-Universitätsmedizin Berlin, Augenklinik, Campus Benjamin Franklin
  • E. Thiel - Charité-Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Benjamin Franklin
  • U. Keilholz - Charité-Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Benjamin Franklin

German Retina Society. 22nd Annual Meeting of the German Retina Society. Berlin, 26.-27.06.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. DocRG2009-60

doi: 10.3205/09rg61, urn:nbn:de:0183-09rg618

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2009/09rg61.shtml

Published: June 29, 2009

© 2009 Schmittel et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

The liver is the predominant site of metastases in the majority of patients with uveal melanoma, suggesting the evaluation of regional treatment approaches. Here we report our experience with TACE in uveal melanoma patients with pretreated liver metastases.Twenty-five patients were treated with fotemustine- or cisplatin-based TACE after treatment failure of systemic therapy between 2003 and 2008 at our institution. Grade III toxicity consisted of gastric ulcer (n=1), fever (n=3), splenic infarction (n=1), and thrombocytopenia (n=1). No grade IV toxicity or catheter associated complications were observed. Fourteen out of 25 patients (56%) had stable disease (SD) for at least 2 months and four a partial (PR). The median progression free survival (PFS) was 3 months (95% CI: 2–4 months) and the median overall survival (OS) was 6 months (95% CI: 5–7 months), with 15% of patients alive at 1 year. Both PFS and OS were significantly longer, if pre-treatment lactate dehydrogenase (LDH) was below the two-fold upper limit of normal (ULN) (n=11): PFS 5 versus 2 months (p<0.001) and OS 11 versus 5 months (p=0.012). All patients with LDH <2xUNL had a clinically detectable benefit.TACE is well tolerated and effective in pre-treated patients with liver metastases from uveal melanoma. TACE should further be evaluated as first line therapy in prospective randomized clinical trials.